Serum GFAP and NfL augment a metabolomics-driven strategy for long-term prediction of multiple sclerosis progression
The integration of metabolic and protein biomarkers enables both accurate staging of RRMS versus SPMS and, critically, early prediction of progression irrespective of stage. This dual capability provides a clinically actionable, serum-based tool that can refine monitoring, improve therapeutic decision-making, and support a shift towards stage-agnostic, progression-focused care in MS.
Authors
- Wenzheng Xiong (ORCID: https://orcid.org/0000-0001-5713-7305)
- Tereza Kačerová (ORCID: https://orcid.org/0000-0002-9477-0182)
- Tianrong Yeo (ORCID: https://orcid.org/0000-0002-3648-0953)
- Megan Sealey
- Johanna Oechtering (ORCID: https://orcid.org/0000-0001-5359-7961)
- Luisa Saldana
- Fay Probert
- Gabriele DeLuca
- Aleksandra Maleska Maceski
- Eline Willemse
- Daniel E. Radford-Smith
- David Leppert
- Daniel C. Anthony
- Jacqueline Palace
- Jens Kuhle
Institutions
- Agency for Science, Technology and Research (SG)
- Nanyang Technological University (SG)
- University of Basel (CH)
- University Hospital of Basel (CH)
- John Radcliffe Hospital (GB)
- University of Oxford (GB)
- Duke-NUS Medical School (SG)
- National Neuroscience Institute (SG)
- Institute of Molecular and Cell Biology (SG)
Publication Details
- Journal
- Communications Medicine
- Published
- 2026-02-25
- DOI
- https://doi.org/10.1038/s43856-026-01453-5
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Oxford
- European Commission
- Engineering and Physical Sciences Research Council